

Jonathan Weber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/333005/publications.pdf>

Version: 2024-02-01

20
papers

1,320
citations

687363

13
h-index

888059

17
g-index

21
all docs

21
docs citations

21
times ranked

2394
citing authors

#	ARTICLE	IF	CITATIONS
1	An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. <i>Journal of Experimental Medicine</i> , 2008, 205, 63-77.	8.5	273
2	HIV-1 DNA predicts disease progression and post-treatment virological control. <i>ELife</i> , 2014, 3, e03821.	6.0	270
3	Short-Course Antiretroviral Therapy in Primary HIV Infection. <i>New England Journal of Medicine</i> , 2013, 368, 207-217.	27.0	194
4	Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005661.	4.7	152
5	Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. <i>Nature Communications</i> , 2015, 6, 8495.	12.8	146
6	Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. <i>Journal of the International AIDS Society</i> , 2014, 17, 19480.	3.0	37
7	Glucopyranosyl Lipid A Adjuvant Significantly Enhances HIV Specific T and B Cell Responses Elicited by a DNA-MVA-Protein Vaccine Regimen. <i>PLoS ONE</i> , 2014, 9, e84707.	2.5	36
8	Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission. <i>Aids</i> , 2010, 24, S27-S39.	2.2	35
9	A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. <i>Frontiers in Immunology</i> , 2017, 8, 149.	4.8	35
10	Structured Observations Reveal Slow HIV-1 CTL Escape. <i>PLoS Genetics</i> , 2015, 11, e1004914.	3.5	30
11	Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen. <i>PLoS ONE</i> , 2015, 10, e0117042.	2.5	27
12	Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design. <i>PLoS ONE</i> , 2018, 13, e0206838.	2.5	25
13	Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. <i>PLoS ONE</i> , 2016, 11, e0155702.	2.5	22
14	How Many HIV Infections May Be Averted by Targeting Primary Infection in Men Who Have Sex With Men? Quantification of Changes in Transmission-Risk Behavior, Using an Individual-Based Model. <i>Journal of Infectious Diseases</i> , 2014, 210, S594-S599.	4.0	11
15	Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. <i>PLoS Pathogens</i> , 2020, 16, e1008522.	4.7	11
16	A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol. <i>Scientific Reports</i> , 2017, 7, 9447.	3.3	8
17	Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence. <i>Frontiers in Immunology</i> , 2019, 10, 717.	4.8	7
18	AIDS. <i>Aids</i> , 2012, 26, 1193.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Testing times for HIV. BMJ, The, 2013, 347, f5556-f5556.	6.0	0
20	Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection SPARTAC cohort. Aids, 2021, Publish Ahead of Print, 2073-2084.	2.2	0